Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, October 5, 2011 Biosign Names New Board Chair and Audit Committee Member
In c9704 transmitted at 13:00 ET, an error occurred in the headline of the release. The headline should read "Biosign Names New Board Chair and Audit Committee Member." Full corrected copy follows:
Biosign Names New Board Chair and Audit Committee Member
TORONTO, Oct. 5, 2011 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) a medical device company focused on non-invasive, cloud-based vitals health monitoring, announced the appointment of Jason D. Meretsky as chairman of its board of directors. The company also announced the appointment of Harold Koplewicz to the audit committee and the resignation of Dr. David Silver from his position as chair and as a member of the board of directors.
Jason D. Meretsky is a corporate securities lawyer with business, transactional and legal experience focused on technology. He brings considerable business experience with early to mid-stage technology and web-based companies. He also brings corporate governance experience to the Biosign board and audit committee having served on several public company boards. Mr. Meretsky is a graduate of the York University Osgoode Hall Law School and obtained his MBA from the Schulich School of Business.
"David Silver joined the Biosign board to focus our business on science and technology. As the company evolved and we move into the commercialization phase of our business, we will be best served by our new chairman," said Scott Jenkins, CEO, Biosign. "We would like to thank David Silver for his time and service guiding our board."
Harold S. Koplewicz, M.D., was appointed to the audit committee to replace Dr. Silver. Dr. Koplewicz is the Chairman of the board of Delcath Systems Inc. and President of the Child Mind Institute, Founder of the NYU Child Center, Member of the National Board of Medical Examiners, and New York State Commissioner of Youth, Crime and Violence and Juvenile System Reform. Dr. Koplewicz is a graduate of Albert Einstein College of Medicine of Yeshiva University.
About Cloud DxTM
The Cloud DxTM brand is a trademark of Biosign Technologies Inc. under which Biosign delivers services to consumers, healthcare professionals and payers. Biosign collects data from proprietary non-invasive devices, uses the cloud for validation, analysis and synthesis of the data, and then makes the information available to patients and their Circle of CareTM. We believe Cloud DxTM is the future of remote healthcare monitoring and quality patient care. For more information, please visit: [ www.clouddx.com ].
About Biosign Technologies Inc
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems through its Cloud DxTM branded solution. Cloud DxTM applications include intelligent systems for non-invasive monitoring of common health risks associated with blood pressure, glucose, and medication. Biosign technology combines measurement, analysis, and tools for disease and patient management to support global vital health monitoring. The UFIT® medical device delivers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation and management, and remote patient monitoring. For more information visit: [ www.biosign.com ].
Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators ([ www.sedar.com ]).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
